US 12,216,114 B2
Isolated organ evaluation and treatment
Magnus Nilsson, Gothenburg (SE); and Anne-Li Sigvardsson, Gothenburg (SE)
Assigned to XVIVO PERFUSION AB, Gothenburg (SE)
Filed by XVIVO Perfusion AB, Gothenburg (SE)
Filed on Jan. 15, 2021, as Appl. No. 17/150,202.
Application 17/150,202 is a continuation of application No. 15/580,901, abandoned, previously published as PCT/EP2016/064645, filed on Jun. 24, 2016.
Claims priority of application No. 1511207 (GB), filed on Jun. 25, 2015.
Prior Publication US 2021/0132044 A1, May 6, 2021
Int. Cl. A01N 1/02 (2006.01); G01N 33/50 (2006.01); G01N 33/68 (2006.01)
CPC G01N 33/5082 (2013.01) [A01N 1/021 (2013.01); A01N 1/0226 (2013.01); G01N 33/6893 (2013.01)] 17 Claims
 
1. A method of treating an isolated organ with existing damage during isolated organ perfusion, wherein the isolated organ is determined during the method to be an isolated organ with existing damage based on comprising cells that have ruptured, the method comprising steps of:
perfusing the isolated organ with a perfusate;
measuring a concentration of a cell rupture marker in the perfusate during the perfusing of the isolated organ;
comparing the concentration of the cell rupture marker in the perfusate to a reference value of the cell rupture marker, as the perfusing of the isolated organ continues, to identify the isolated organ as comprising cells that have ruptured;
adding a tissue factor (TF) suppressor molecule to the perfusate, as the perfusing of the isolated organ continues, only after having identified the isolated organ as comprising cells that have ruptured; and
further perfusing the isolated organ with the perfusate after the TF suppressor molecule has been added, thereby treating the isolated organ, wherein
the cell rupture marker comprises one or more of double stranded DNA (dsDNA), mitochondrial DNA, or ribosomes; and
the TF suppressor molecule comprises a cyclooxygenase (COX) inhibitor.